JNJ-7925476

JNJ-7925476

JNJ-7925476
Systematic (IUPAC) name
(±)-(6S,10bR)-6-(4-ethynylphenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline
Clinical data
Legal status
?
Identifiers
ATC code ?
Chemical data
Formula C20H19N 
Mol. mass 273.371
 YesY   

JNJ-7925476 is a TRI antidepressant currently under development by Johnson & Johnson.[1]

These molecules were first prepared by Bruce E. Maryanoff, et al. during the late 1970s – 1980's.[2][3][4] and is known as a pyrroloisoquinoline, that is benzhydryl-containing.

Incorporating the pyrrolidino ring onto the THIQ scaffolding markedly improves potency, although this only works for one of the available diastereo/enantiomers. JNJ-7925476 is a racemic preparation of the more potent diastereomer. The eutomer, JNJ-39836966 has (6R,10bS)-stereochemistry whereas the distomer JNJ-39836732 will have (6S,10bR)-stereochemistry.

The compounds depicted appear to be cis but Maryanoff and coworkers are of the opinion that it is trans.[1] (see abstract)

The reason for this is not known because it was referred to as "cis" to begin with, only reassigning it later.

Cyclohexane conformation

In-vitro characterization

Ki values (nM) for JNJ-7925476 and its constituent enantiomers (JNJ-39836966 and JNJ-39836732)
JNJ rSERT hSERT hDAT hNET
7925476 0.4 0.9 5.2 16.6
39836966 0.33 0.27 1.6 15.8
39836732 17.0 4.1 74.3 227

In vitro, JNJ-7925476 is ~18-fold selective for the hSERT (0.9 nM) over the hNET (16.6 nM).

Ex vivo transporter occupancy of JNJ-7925476 (in rat brain) followed the ordering priority: NET > SERT > DAT.

This is consistent with the results cited earlier for rat brains (see SAR table dated 1987).

However, there is relatively poor correlation between the in vitro data presented for rats brains vs what was reported at the human transporters.

μ-Dialysis

Elevations in extracellular DA in vivo was higher than expected on the basis of the in vitro transporter affinities.

The authors speculate that this could be because in the PFC where DATs are low in number, DA is predominantly transported via the NET.[5]

  • ~ 1 mg/kg of JNJ-7925476 caused concentrations of NE, 5-HT and DA to all be elevated by just under 500%, respectively.

Ex vivo occupancy of the DAT was much lower (<50%) at this dose though, whereas the NET and SERT were similar (~90%).

It took a much higher dose (c.f. 10 mg/kg) for the DAT occupancy to approach the same as the NET and SERT (i.e. saturation).

At saturation, the elevation in synaptic DA was extremely prolific (15 × baseline), whereas SER and NE was ≈ ½ this amount (i.e. 750%).

Pyrroloisoquinolines structure activity relationships

3d structure, Y = OMe
X Y V W MA (mg/kg) ptosis (mg/kg) DA (nM) NE (nM) 5-HT (nM)
H H H H 0.34 (0.59) 0.07 (0.05) 11.3 (4.4) 0.60 (0.37) 23.5 (12.4)
H H OMe OMe 15.1 3.8 15.0 53.7 1540
H H OH OH 0.87 0.53 43.5 10.5 124
OMe H H H 0.27 0.03 5.2 0.79 1.7
OH H H H 0.40 0.09 5.1 0.74 3.2
H OMe H H ~0.2 0.07 15.8 0.65 7.2
H OH H H >10 0.11 10.1 0.85 24.6
H H H OMe no data no data 2.8 2.2 4.5
OMe OMe H H 2.0 0.13 71.9 3.4 18.1
OH OH H H 0.19 0.11 10.1 0.81 33.1
Cl H H H 0.55 0.34 1.7 0.16 1.5
H Cl H H ~0.1 <0.1 2.5 0.45 7.3
Cl H H Cl 37.4 ~4 3.2 3.2 2.9
Cl Cl H H 0.39 0.14 0.99 0.68 1.8
F H H H ~0.2 ~0.2 8.4 1.4 8.5
F H H F >30 0.05 7.7 0.55 4.4
NH2 H H H ~0.2 ~0.01 0.86 0.20 44
SMe H H H >30 (no data) 0.30 (no data) 41.2 (23.5) 3.0 (1.8) 0.62 (0.39)
Ethynyl H H H ~0.5 ~0.5 2.6 0.94 1.0
diclofensine 10.9 8.8 10.3
WIN-25978 7.2 41.1 879

This is a collection of all of the analogs that had favorable biological activity or an interesting substitution pattern.

All compounds are racemic preparations with the exception that brackets are for pure (+) enantiomer.

Ring size structure activity relationships

Expanding the ring size from pyrrolidino to piperidinyl resulted in compounds that were impotent, although contracting the ring size from 5 → 4 did not have negative repercussions on the resultant potency.

Chemistry

The N-acyliminium cyclization route; and the mandelic acid and styrene oxide route were employed for most of the target compounds.

Pyrroloisoquinoline Synthesis

The SS/RR diastereomers as the principle products if one follows the above steps.[6][7]

It is possible to epimerize the product to the desired RS/SR diastereomers, but the equilibrium is only 50/50.

Hence, alternative synthetic methods needed to be sought to obtain the desired isomer/s in diastereochemical excess.

If instead of an "aryl" group, a tert-butyl or a cyclohexyl was used, then it was possible to alter the stereochemical discourse of the reaction.[8]

Stereoselective reaction

U.S. Patent 4,837,328

Hydrogenation of an appropriately positioned olefin might be expected to work.[9][10]

But the ketone cannot be reduced to an alcohol because it is part of an amide.

2,2-diphenylethylamine[11] (doi:10.1021/ja01614a053 doi:10.1021/jo00067a033)

2-Phenylpyrrolidine

Relevant patents

U.S. Patent 6,162,417 U.S. Patent 4,713,386 U.S. Patent 4,719,216 U.S. Patent 4,595,688 U.S. Patent 4,837,328 U.S. Patent 4,572,911

References

  1. ^ a b Aluisio, L.; Lord, B.; Barbier, A.; Fraser, I.; Wilson, S.; Boggs, J.; Dvorak, L.; Letavic, M.; Maryanoff, B.; Carruthers, N. I.; Bonaventure, P.; Lovenberg, T. W. (2008). "In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor". European Journal of Pharmacology 587 (1–3): 141–146.  
  2. ^ Maryanoff, B. E.; Mccomsey, D. F.; Castanzo, M. J.; Setler, P. E.; Gardocki, J. F.; Shank, R. P.; Schneider, C. R. (1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin".  
  3. ^ Maryanoff, B. E.; Mccomsey, D. F.; Gardocki, J. F.; Shank, R. P.; Costanzo, M. J.; Nortey, S. O.; Schneider, C. R.; Setler, P. E. (1987). "Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships".  
  4. ^ Maryanoff, B. E.; Vaught, J. L.; Shank, R. P.; Mccomsey, D. F.; Costanzo, M. J.; Nortey, S. O. (1990). "Pyrroloisoquinoline antidepressants. 3. A focus on serotonin". Journal of Medical Chemistry 33 (10): 2793–2797.  
  5. ^ Morón, J. A.; Brockington; Wise; Rocha; Hope (2002). "Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines". Journal of Neuroscience 22 (2): 389–395.  
  6. ^ Maryanoff, B. (1979). "Iminium ion cyclizations. Highly stereoselective synthesis of substituted tetrahydroisoquinoline derivatives". Tetrahedron Letters 20 (40): 3797–3800.  
  7. ^ Maryanoff, B. E.; Mccomsey, D. F.; Duhl-Emswiler, B. A. (1983). "Stereochemistry of intramolecular amidoalkylation reactions in the synthesis of polycyclic isoquinoline derivatives". The Journal of Organic Chemistry 48 (25): 5062.  
  8. ^ Maryanoff, B. E.; Mccomsey, D. F.; Almond, H. R.; Mutter, M. S.; Bemis, G. W.; Whittle, R. R.; Olofson, R. A. (1986). "Dramatic reversal of diastereoselectivity in an N-acyliminium ion cyclization leading to hexahydropyrrolo[2,1-a]isoquinolines. A case of competing steric interactions". The Journal of Organic Chemistry 51 (8): 1341.  
  9. ^ Maryanoff, B. E.; Mccomsey, D. F.; Mutter, M. S.; Sorgi, K. L.; Maryanuff, C. A. (1988). "Highly stereocontrolled proton transfer in an enammonium-iminium rearrangement. Mechanism of the stereoselective deoxygenation of 6-aryl-6-hydroxy-1,2,3,5,6,10b-hexahydropyrrolo[2.1-]isoquinolines with borane-thf in trifluoroacetic acid". Tetrahedron Letters 29 (40): 5073.  
  10. ^ Mccomsey, D. F.; Maryanoff, B. E. (2000). "3-Aza-cope rearrangement of quaternary N-allyl enammonium salts. Stereospecific 1,3 allyl migration from nitrogen to carbon on a tricyclic template". The Journal of Organic Chemistry 65 (16): 4938–4943.  
  11. ^ Maryanoff, B. E.; Nortey; Gardocki (1984). "Structure-activity studies on antidepressant 2,2-diarylethylamines". Journal of Medical Chemistry 27 (8): 1067–1071.  

This article was sourced from Creative Commons Attribution-ShareAlike License; GNU Free Documentation License; additional terms may apply; additional licensing terms may not be displayed on the current page, please review the citiational source for the most up to date information. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.


Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.


By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia is a registered trademark of the World Public Library Association, a non-profit organization.